This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

20 Apr 2011

SciClone Acquires China-based Specialty Pharma

SciClone Pharmaceuticals Inc. bought NovaMed Pharmaceuticals Inc., a Chinese specialty pharmaceutical company, in a cash and stock deal worth up to nearly $105 million.

Foster City, CA-based SciClone Pharmaceuticals has inked a deal to buy Shanghai-based NovaMed Pharmaceuticals for $24.7 million in cash and $37.1 million in stock. SciClone has also pledged up to $43 million in revenue milestones as it absorbs a developer with a range of marketed drugs as well as a development arm focused on registration work.


NovaMed has a portfolio of 18 drug products covering four therapeutic areas: Oncology, cardiovascular disease, central nervous system disorders and urology/infection. And SciClone says that it will step up to the plate in China with additional programs up for regulat

Related News